Search clinical trials for: MK-3475

Total 2278 results

University of Washington
National Cancer Institute (NCI); United States Department of Defense

Recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Washington
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer AJCC v8

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 Positive

United States
Monica Mita
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Lynch Syndrome | Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Refractory Ependymoma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Refractory Diffuse Intrinsic Pontine Glioma | Recurrent Brain Neoplasm | Refractory Brain Neoplasm | Constitutional...

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Neuroendocrine Neoplasm | Extensive Stage Small Cell Lung Carcinoma | Limited Stage Small Cell Lung Carcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive)... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Poland, Romania, Ukraine, Chile, Canada, United States, Argentina, China, Czechia, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Norway, Peru, Russian Federation, Spain, Thailand, Turkey, United...
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Desmoplastic Melanoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Ovarian Carcinoma | High-grade Serous Ovarian Carcinoma

Korea, Republic of, Spain, Poland, United States, Belgium, Canada, Chile, Israel, Italy, Singapore, Taiwan
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Glioblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Advanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Cancer | Stage IV Lung Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
Floor Backes, MD

Active, not recruiting

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Stage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Rutgers Cancer Institute...

Active, not recruiting

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Lymphoma | Metastatic Melanoma | Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm and other conditions

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Terminated

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Adult Glioblastoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
University of California, Davis
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

KRAS Gene Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
Syndax Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Melanoma | Non-Small Cell Lung Cancer | Mismatch Repair-Proficient Colorectal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
University of Washington
TG Therapeutics, Inc.

Terminated

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin's Lymphoma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States

Search clinical trials for: MK-3475

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations